Factorization of polynomials

Neurologist Anthony Lang Presents Groundbreaking News on Parkinson's Disease at World Congress of Neurology 2023

Retrieved on: 
Tuesday, October 17, 2023
Diagnosis, Parkinson's disease, Congress, Medicine, Quality of life, Biomarker, Death, Research, Biology, Brain, Epidemiology, MSA, University, Health, Classification, Disease, University of Toronto, Neurodegenerative disease, Factorization of polynomials, Center for Global Infectious Disease Research, Cohort (statistics), Multiple system atrophy, Skin, Blood, WCN, Patient, Pharmaceutical industry, Medical imaging, Vaccine, Neurology

MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.

Key Points: 
  • MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.
  • "We believe this is a radically different way of looking at Parkinson's disease," said Lang.
  • Lang hopes this major step toward a biological model will drive research to investigate these biomarkers and give scientists a more complex understanding of the disease.
  • We need treatments that will slow the progression and change the natural course of these neurodegenerative diseases," said Lang.

Neurologist Anthony Lang Presents Groundbreaking News on Parkinson's Disease at World Congress of Neurology 2023

Retrieved on: 
Tuesday, October 17, 2023
Diagnosis, Parkinson's disease, Congress, Medicine, Quality of life, Biomarker, Death, Research, Biology, Brain, Epidemiology, MSA, University, Health, Classification, Disease, University of Toronto, Neurodegenerative disease, Factorization of polynomials, Center for Global Infectious Disease Research, Cohort (statistics), Multiple system atrophy, Skin, Blood, WCN, Patient, Pharmaceutical industry, Medical imaging, Vaccine, Neurology

MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.

Key Points: 
  • MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.
  • "We believe this is a radically different way of looking at Parkinson's disease," said Lang.
  • Lang hopes this major step toward a biological model will drive research to investigate these biomarkers and give scientists a more complex understanding of the disease.
  • We need treatments that will slow the progression and change the natural course of these neurodegenerative diseases," said Lang.

Lucy Therapeutics Expands Cutting-Edge Medical Research Program

Retrieved on: 
Wednesday, October 11, 2023
Health, Other Health, Other Science, General Health, Research, Science, Biotechnology, Walking, Eating, Biomarker, Hope, IRSF, University of Utah, Genetics, University, McGruder, Disease, Speech, Factorization of polynomials, Patient, Bangladesh Technical Education Board, Drug discovery, DSM-IV codes, Rett syndrome, Pharmaceutical industry

Lucy Therapeutics (LucyTx) has secured new funding from the International Rett Syndrome Foundation (IRSF) to invest in pioneering treatments for children and adults living with Rett syndrome, and to grow LucyTx’s groundbreaking treatment platform.

Key Points: 
  • Lucy Therapeutics (LucyTx) has secured new funding from the International Rett Syndrome Foundation (IRSF) to invest in pioneering treatments for children and adults living with Rett syndrome, and to grow LucyTx’s groundbreaking treatment platform.
  • Rett syndrome affects brain development in infants and toddlers, with missed growth milestones or regression typical around six to 18 months.
  • “A treatment that can help stop Rett syndrome will help improve so many lives.” Hallsey wrote a children’s book, “Matilda McGruder,” in 2021 that benefitted Rett syndrome research.
  • IRSF is a mission-driven advocacy foundation focused on funding research and supporting families impacted by Rett syndrome.

Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Clinical Trials, Medicinal chemistry, Bone cancer in cats and dogs, Surgeon, Therapy, Drug discovery, Head, Osteosarcoma, Bone, Research, Merck & Co., Factorization of polynomials, Prostaglandin, Former, Metastasis, New York Blood Center, Patient, CBO, Chronic kidney disease-mineral and bone disorder, Chief financial officer, Merck, EP4, Elective surgery, Safety, Pharmaceutical industry, Medical imaging, Dentistry

Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.

Key Points: 
  • Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.
  • The bone is a complex, dynamic tissue with unique properties that make it a formidable challenge for drug efficient penetration.
  • The company successfully dosed the first patients via subcutaneous injection in a Phase 1 study evaluating MES1022, a bone-selective EP4 receptor agonist prodrug they are developing for bone regeneration, with the first application for accelerating healing of bone fractures.
  • “MES1022 is well-positioned to be the first therapy that mimics and enhances the natural processes the body uses to stimulate bone repair and healing.

Kanazawa University research: Researchers identify the dynamic behavior of a key SARS-CoV-2 accessory protein

Retrieved on: 
Tuesday, September 26, 2023
Infection, Spontaneous, Urea, SARS-CoV-2, ORF6, Fever, COVID-19, Survival, Alcohol, Lipid, Polymer, Cytoplasm, Sodium dodecyl sulfate, Messenger, XXX, Behavior, The Journal of Physical Chemistry Letters, Protein, Journal, Sickness, Physical chemistry, Observation, Chiba University, Immune system, Environment, Virus, Factorization of polynomials, AFM, ORF, Disease, Kanazawa University, Microscope, Vaccine, COVID19

With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.

Key Points: 
  • With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.
  • "Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report.
  • However, the mechanism for this protein retention and transport disruption was not clear.
  • To shed light on these mechanisms the researchers first looked into what clues various software programs might give as to the structure of ORF6.

Kanazawa University research: Researchers identify the dynamic behavior of a key SARS-CoV-2 accessory protein

Retrieved on: 
Tuesday, September 26, 2023
Infection, Spontaneous, Urea, SARS-CoV-2, ORF6, Fever, COVID-19, Survival, Alcohol, Lipid, Polymer, Cytoplasm, Sodium dodecyl sulfate, Messenger, XXX, Behavior, The Journal of Physical Chemistry Letters, Protein, Journal, Sickness, Physical chemistry, Observation, Chiba University, Immune system, Environment, Virus, Factorization of polynomials, AFM, ORF, Disease, Kanazawa University, Microscope, Vaccine, COVID19

With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.

Key Points: 
  • With this in mind there has been a lot of interest in the accessory proteins that the virus produces to help it thrive in the body.
  • "Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report.
  • However, the mechanism for this protein retention and transport disruption was not clear.
  • To shed light on these mechanisms the researchers first looked into what clues various software programs might give as to the structure of ORF6.

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

Retrieved on: 
Monday, September 18, 2023
JPMorgan Chase, BS, Depression, Goldman, Chronic kidney disease, Senior, Health, Goldman Sachs, Biotechnology, Allergan, Cancer, MBA, Infection, COMPASS, Merck & Co., AstraZeneca, MS, Massachusetts Institute of Technology, Hypertension, Anorexia nervosa, Aldosterone, Acquisition, Post-traumatic stress disorder, AbbVie, Flare, Patient, Chemical engineering, Corporation, Factorization of polynomials, Harvard Business School, Merck, CMPS, Treasurer, Therapy, Mental health, Pharmaceutical industry, Nursing

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023.

Key Points: 
  • LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023.
  • Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
  • “Daphne is an ideal match for the COMPASS Pathways Board of Directors as we progress our phase 3 COMP360 psilocybin program in treatment-resistant depression and our phase 2 programs in anorexia nervosa and post-traumatic stress disorder,” said George Goldsmith, Chairman of the COMPASS Pathways Board of Directors.
  • We are delighted to welcome her.”
    “I am excited to join the COMPASS board as the company advances its pioneering COMP360 psilocybin program,” said Ms. Karydas.

Lego-Like Gene Editing Tool Lets Researchers Improve Cancer Immunotherapy

Retrieved on: 
Thursday, September 14, 2023
Lymphoma, Molecular biology, War, DNA, CRISPR, Brain, Stanford School, Therapy, TFAP4, Gene editing, Bone marrow, University of California, San Francisco, Cancer, Doctor of Philosophy, BATF, CAR, MD, UCSF, Patient, Pathology, SAN, Canadian Aviation Regulations, William Ewart Gladstone, Lego, Atlas, Gladstone Institutes, Leukemia, Gene, Factorization of polynomials, Vaccine, Pharmaceutical industry, Marson, Cell

SAN FRANCISCO, Sept. 14, 2023 /PRNewswire/ -- In recent years, scientists have used gene modification technologies to reprogram immune cells into therapeutics that can attack cancers. But such immunotherapies don't work for all patients or all cancer types, and screening through every possible combination of genetic changes that might improve these reprogrammed immune cells is a daunting and slow task.

Key Points: 
  • When a T cell recognizes a cancer cell as foreign, through a receptor on its surface, it targets the cancer cell for destruction.
  • The technology combines multiple genes into long stretches of DNA for use in a CRISPR gene editing platform.
  • An easy-to-read DNA barcode on each ModPoKI-generated set of genes let them track which gene combination led to improved T cells.
  • "In the lab, the ModPoKI sequence with BATF and TFAP4 made CAR T cells show potential to improve anti-tumor activity," says Marson.

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Retrieved on: 
Tuesday, September 12, 2023
Oxidative phosphorylation, Pancreatic cancer, NF, University, Cell death, GAPDH, Glomus tumor, ATP, Enzyme, Agonal respiration, Quality of life, Cancer, Research, Ruhr University Bochum, Molecular medicine, University of Duisburg-Essen, Patient, Manuscript, Apoptosis, Organ (biology), Journal of Cellular and Molecular Medicine, ST, Factorization of polynomials, Pharmaceutical industry, Panaveli

BERWYN, PA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells1.” The publication by Majchrzak-Stiller, et al. (2023) details the multiple sites of action of GP-2250 in the disruption of energy production of cancer cells and the downregulation of tumor promoting transcription factors.

Key Points: 
  • GP-2250 is a highly selective yet broadly active cancer therapeutic with a unique mechanism of action that suppresses cancer by disrupting its energy metabolism, leading to cancer cell death through several validated mechanisms.
  • GP-2250 is currently being studied in a Phase 1 clinical trial for pancreatic cancer.
  • Results of the preclinical study showed that at the lowest dose of GP-2250 tested (250 μM), a significant decrease in ATP was apparent at 6 hours in both pancreatic cancer cell lines.
  • We are pleased with the results GP-2250 demonstrated, and the metabolic and transcriptional findings provide molecular targets for GP-2250.

Menstrual leave, neurodiversity, chronic illnesses: what if workplaces adapted to our bodies?

Retrieved on: 
Thursday, August 31, 2023
Portrait of Madame Cézanne with Loosened Hair, Small business, Pregnancy, Awareness, Diabetes, Attention deficit hyperactivity disorder predominantly inattentive, Developmental coordination disorder, Solution, Culture, Workplace, Woman, Research, Factorization of polynomials, Lung, Down syndrome, Science, Insomnia, School, Literature, Population, Metabolism, Time, Risk, Income, Cancer, Menopause, Spectrum, Google, Tetraplegia, Logic, United Kingdom, Knowledge, Conditional sentence, Health, Dyslexia, Bird, Remuneration, Chronic pain, Family, Sick leave, Caregiver, Rheumatoid arthritis, Pharmaceutical industry, Nursing, Dietary supplement, Health insurance, Management, EU

For those suffering from health issues especially, the past weeks will have provided a well-needed break from the daily grind, or what the French would colourfully refer to métro-boulot-dodo (metro-work-sleep).

Key Points: 
  • For those suffering from health issues especially, the past weeks will have provided a well-needed break from the daily grind, or what the French would colourfully refer to métro-boulot-dodo (metro-work-sleep).
  • So, are timetables and workplaces based on our individual biologies the way forward?

Considering biological factors

    • I experienced a chronic condition myself and tried to adjust in my work as a professor at a school of management.
    • Looking at current research from various scientific disciplines, it is possible to distinguish between three broad biological conditions that have repercussions on people’s ability to work:

Band-aid solutions

    • More formal solutions are also riddled with shortcomings.
    • Too often, the status also carries too heavy a stigma, with many opting out for reasons of pride.
    • Hence, so-called key employees may get what they want by contrast with employees who are seen as underperforming.
    • Instead, a growing number of companies offer the possibility of flexible working Link to their employees on the condition that they fulfil their obligations.

When teamwork takes the hit

    • Inevitably, such arrangements come at the cost of the company’s teamwork and collective productivity.
    • And that’s without forgetting that colleague’s exemption from using certain work tools due to their neurodiversity.
    • Nearly a quarter of managerial staff (24%) report using sleeping pills or anti-depressants compared to 18% of employees.

Retraining managers

    • For example, research on the retention of employees suffering from rheumatoid arthritis showed the importance of managers having knowledge or personal experience of the disability in terms of introducing policies that would be beneficial to both employee and employer.
    • If that approach is to be successful, managers will also need to abandon the idea of being the perfect supervisor and accepting their limits.

Collective, not individual solutions

    • Looking away from a frazzled patchwork of individual solutions, an increasing number of companies and governments are contemplating organisational shifts benefiting all, including in terms of working days.
    • It can also prevent envy toward what can be perceived as the material privileges of those living with a condition.
    • Most will agree that those living with chronic illness, neurodiversity or/and different circadian rhythms deserve our full support.